Belite Bio Inc reports results for the quarter ended June 30 - Earnings Summary

• Belite Bio Inc BLTE.OQ reported a quarterly adjusted loss of 50 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -31 cents. The mean expectation of four analysts for the quarter was for a loss of 42 cents per share. Wall Street expected results to range from -48 cents to -30 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Belite Bio Inc's reported EPS for the quarter was a loss of 50 cents​.

• The company reported a quarterly loss of $16.32 million.

• Belite Bio Inc shares had risen by 21.1% this quarter and gained 10.7% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 14.1% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Belite Bio Inc is $92.50, about 24.5% above its last closing price of $69.88

This summary was machine generated from LSEG data August 11 at 09:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)